CD19 and infection: Basiliximab treatment did not inhibit the B cells, and we observed that the IR of CD19+ B cells in patients who recovered from SR-aGVHD was similar to that in event-free HID HSCT recipients, which may help to prevent the late infections in SR-aGVHD survivors.